Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

Published:October 12, 2021DOI:https://doi.org/10.1016/j.eprac.2021.09.016

      Abstract

      Objective

      The goal of this randomized, double-blinded, placebo-controlled clinical trial was to investigate the therapeutic efficacy of oral 25-hydroxyvitamin D3 (25(OH)D3) in improving vitamin D status in vitamin D–deficient/vitamin D–insufficient patients infected with the SARS-CoV-2 (COVID-19) virus.

      Methods

      This is a multicenter, randomized, double-blinded, placebo-controlled clinical trial. Participants were recruited from 3 hospitals that are affiliated to [Institution Blinded for Review] and [Institution Blinded for Review].

      Results

      A total 106 hospitalized patients who had a circulating 25(OH)D3 concentration of <30 ng/mL were enrolled in this study. Within 30 and 60 days, 76.4% (26 of 34) and 100% (24 of 24) of the patients who received 25(OH)D3 had a sufficient circulating 25(OH)D3 concentration, whereas ≤12.5% of the patients in the placebo group had a sufficient circulating 25(OH)D3 concentration during the 2-month follow-up.
      We observed an overall lower trend for hospitalization, intensive care unit duration, need for ventilator assistance, and mortality in the 25(OH)D3 group compared with that in the placebo group, but differences were not statistically significant. Treatment with oral 25(OH)D3 was associated with a significant increase in the lymphocyte percentage and decrease in the neutrophil-to-lymphocyte ratio in the patients. The lower neutrophil-to-lymphocyte ratio was significantly associated with reduced intensive care unit admission days and mortality.

      Conclusion

      Our analysis indicated that oral 25(OH)D3 was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 that resulted in improved immune function by increasing blood lymphocyte percentage. Randomized controlled trials with a larger sample size and higher dose of 25(OH)D3 may be needed to confirm the potential effect of 25(OH)D3 on reducing clinical outcomes in patients with COVID-19.

      Key words

      Abbreviations:

      CI (confidence interval), ICU (intensive care unit), IQR (interquartile range), LDH (lactate dehydrogenase), NLR (neutrophil-to-lymphocyte ratio), OR (odds ratio), 1,25(OH)2D (1,25-dihydroxyvitamin D), RCT (randomized controlled trials), SMD (standardized mean difference), 25(OH)D3 (25-hydroxyvitamin D3)
      To read this article in full you will need to make a payment
      AACE Member Login
      AACE Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. COVID 19 information. Accessed Month DD, YYYY.
        https://covid19.continualflight.com/
        Date accessed: May 13, 2021
        • Lippi G.
        • Plebani M.
        Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis.
        Clin Chim Acta. 2020; 505: 190-191
        • Guan W.J.
        • Liang W.H.
        • Zhao Y.
        • et al.
        Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.
        Eur Respir. 2020; 55: 2000547
        • Martineau A.R.
        • Jolliffe D.A.
        • Hooper R.L.
        • et al.
        Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.
        BMJ. 2017; 356: i6583
        • Maghbooli Z.
        • Sahraian M.A.
        • Ebrahimi M.
        • et al.
        Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection.
        PloS One. 2020; 15e0239799
        • Kaufman H.W.
        • Niles J.K.
        • Kroll M.H.
        • Bi C.
        • Holick M.F.
        SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels.
        PloS One. 2020; 15e0239252
        • Pereira M.
        • Dantas Damascena A.
        • Galvão Azevedo L.M.
        • de Almeida Oliveira T.
        • da Mota Santana J.
        Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis.
        Crit Rev Food Sci Nutr. 2020; : 1-9
        • Murai I.H.
        • Fernandes A.L.
        • Sales L.P.
        • et al.
        Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial.
        JAMA. 2021; 325: 1053-1060
        • Entrenas Castillo M.
        • Entrenas Costa L.M.
        • Vaquero Barrios J.M.
        • et al.
        Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study.
        J Steroid Biochem Mol Biol. 2020; 203: 105751
        • Grant W.B.
        • Lahore H.
        • McDonnell S.L.
        • et al.
        Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths.
        Nutrients. 2020; 12: 988
        • Goncalves-Mendes N.
        • Talvas J.
        • Dualé C.
        • et al.
        Impact of vitamin D supplementation on influenza vaccine response and immune functions in deficient elderly persons: a randomized placebo-controlled trial.
        Front Immunol. 2019; 10: 65
        • Misra D.P.
        • Agarwal V.
        • Gasparyan A.Y.
        • Zimba O.
        Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
        Clin Rheumatol. 2020; 39: 2055-2062
        • Holick M.F.
        • Binkley N.C.
        • Bischoff-Ferrari H.A.
        • et al.
        Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2011; 96: 1911-1930
        • Quesada-Gomez J.M.
        • Bouillon R.
        Is calcifediol better than cholecalciferol for vitamin D supplementation?.
        Osteoporos Int. 2018; 29: 1697-1711
        • Biancuzzo R.M.
        • Clarke N.
        • Reitz R.E.
        • Travison T.G.
        • Holick M.F.
        Serum concentrations of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 supplementation.
        J Clin Endocrinol Metab. 2013; 98: 973-979
        • Bischoff-Ferrari H.A.
        • Dawson-Hughes B.
        • Stöcklin E.
        • et al.
        Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity.
        J Bone Miner Res. 2012; 27: 160-169
        • Cesareo R.
        • Falchetti A.
        • Attanasio R.
        • Tabacco G.
        • Naciu A.M.
        • Palermo A.
        Hypovitaminosis D: is it time to consider the use of calcifediol?.
        Nutrients. 2019; 11: 1016
        • Bouillon R.
        • Marcocci C.
        • Carmeliet G.
        • et al.
        Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions.
        Endocr Rev. 2019; 40: 1109-1151
        • Hossein-Nezhad A.
        • Holick M.F.
        Vitamin D for health: a global perspective.
        Mayo Clin Proc. 2013; 88: 720-755
        • Maghbooli Z.
        • Omidifar A.
        • Varzandi T.
        • Salehnezhad T.
        • Sahraian M.A.
        Reduction in circulating vitamin D binding protein in patients with multiple sclerosis.
        BMC Neurol. 2021; 21: 168
        • Charoenngam N.
        • Holick M.F.
        Immunologic effects of vitamin D on human health and disease.
        Nutrients. 2020; 12: 2097
        • Sosa Henríquez M.
        • Gómez de Tejada Romero M.J.
        Cholecalciferol or calcifediol in the management of vitamin D deficiency.
        Nutrients. 2020; 12: 1617
        • Navarro-Valverde C.
        • Sosa-Henríquez M.
        • Alhambra-Expósito M.R.
        • Quesada-Gómez J.M.
        Vitamin D3 and calcidiol are not equipotent.
        J Steroid Biochem Mol Biol. 2016; 164: 205-208
        • Barger-Lux M.J.
        • Heaney R.P.
        • Dowell S.
        • Chen T.C.
        • Holick M.F.
        Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men.
        Osteoporos Int. 1998; 8: 222-230
        • Charoenngam N.
        • Kalajian T.A.
        • Shirvani A.
        • et al.
        A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption.
        Am J Clin Nutr. 2021; 114: 1189-1199
        • Hewison M.
        Vitamin D and the immune system: new perspectives on an old theme.
        Endocrinol Metab Clin North Am. 2010; 39: 365-379
        • Denman A.M.
        Lymphocyte function and virus infections.
        J Clin Pathol Suppl (R Coll Pathol). 1979; 13: 39-47
        • Huang W.
        • Berube J.
        • McNamara M.
        • et al.
        Lymphocyte subset counts in COVID-19 patients: a meta-analysis.
        Cytometry A. 2020; 97: 772-776
        • Borges L.
        • Pithon-Curi T.C.
        • Curi R.
        • Hatanaka E.
        COVID-19 and neutrophils: the relationship between hyperinflammation and neutrophil extracellular traps.
        Mediators Inflamm. 2020; 2020: 8829674
        • Lagunas-Rangel F.A.
        Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis.
        J Med Virol. 2020; 92: 1733-1734
        • Alcala-Diaz J.F.
        • Limia-Perez L.
        • Gomez-Huelgas R.
        • et al.
        Calcifediol treatment and hospital mortality due to COVID-19: a cohort study.
        Nutrients. 2021; 13: 1760
        • Nogues X.
        • Ovejero D.
        • Pineda-Moncusí M.
        • et al.
        Calcifediol treatment and COVID-19-related outcomes.
        J Clin Endocrinol Metab. 2021; 106: e4017-e4027
        • Annweiler C.
        • Hanotte B.
        • Grandin de l'Eprevier C.
        • Sabatier J.M.
        • Lafaie L.
        • Célarier T.
        Vitamin D and survival in COVID-19 patients: a quasi-experimental study.
        J Steroid Biochem Mol Biol. 2020; 204: 105771
        • Chen N.
        • Zhou M.
        • Dong X.
        • et al.
        Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
        Lancet. 2020; 395: 507-513
        • Wu Z.
        • McGoogan J.M.
        Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.
        JAMA. 2020; 323: 1239-1242
        • Xu Z.
        • Shi L.
        • Wang Y.
        • et al.
        Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
        Lancet Respir Med. 2020; 8: 420-422
        • McCullough P.J.
        • Lehrer D.S.
        • Amend J.
        Daily oral dosing of vitamin D3 using 5000 to 50,000 international units a day in long-term hospitalized patients: insights from a seven year experience.
        J Steroid Biochem Mol Biol. 2019; 189: 228-239

      Linked Article

      • Vitamin D for COVID-19 on Trial: An Update on Prevention and Therapeutic Application
        Endocrine Practice Vol. 27Issue 12
        • Preview
          The results of a pilot, randomized, placebo-controlled, double-blind clinical trial of calcifediol calcifediol {25-hydroxyvitamin D3 [25(OH)D3]} treatment in 106 COVID-19 patients in Iran are presented in an article in this issue.1 The primary significant effects of calcifediol treatment were an increase in lymphocyte percentage and a decrease in the ratio of neutrophils to lymphocytes in the patients. In addition, there were modest trends for hospitalization, intensive care unit duration, needing ventilator assistance, and mortality in the calcifediol group compared to the placebo group.
        • Full-Text
        • PDF